Varbo Anette, Nordestgaard Børge G
aDepartment of Clinical Biochemistry bThe Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital cFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Curr Opin Lipidol. 2017 Aug;28(4):300-307. doi: 10.1097/MOL.0000000000000429.
To review recent advances in the field of remnant lipoproteins and remnant cholesterol with a focus on cardiovascular disease risk.
In line with previous years' research, current observational, genetic, and mechanistic studies find remnant lipoproteins (defined in different ways) to be involved in atherosclerosis development and cardiovascular disease risk. High concentrations of remnant cholesterol could explain some of the residual risk of cardiovascular disease seen after LDL cholesterol lowering. This will be increasingly important as populations worldwide become more obese and more have diabetes, both of which elevate remnant cholesterol concentrations. Many smaller scale studies and post hoc analyses show that remnant cholesterol can be lowered by different types of drugs; however, results from large scale studies with the primary aim of reducing cardiovascular disease risk through lowering of remnant cholesterol in individuals with elevated concentrations are still missing, although some are under way.
Remnant cholesterol is a risk factor for cardiovascular disease, and can be lowered by different types of drugs; however, large scale studies of cardiovascular disease risk reduction through remnant lipoprotein lowering are under way.
综述残余脂蛋白和残余胆固醇领域的最新进展,重点关注心血管疾病风险。
与前几年的研究一致,当前的观察性、遗传学和机制研究发现残余脂蛋白(以不同方式定义)与动脉粥样硬化发展和心血管疾病风险有关。高浓度的残余胆固醇可以解释低密度脂蛋白胆固醇降低后仍存在的部分心血管疾病残余风险。随着全球人口变得更加肥胖且糖尿病患者增多,这两者都会升高残余胆固醇浓度,这一点将变得越来越重要。许多小规模研究和事后分析表明,不同类型的药物可以降低残余胆固醇;然而,以降低高浓度个体的残余胆固醇从而降低心血管疾病风险为主要目的的大规模研究结果仍未得出,不过有些研究正在进行中。
残余胆固醇是心血管疾病的一个危险因素,不同类型的药物可以降低它;然而,通过降低残余脂蛋白来降低心血管疾病风险的大规模研究正在进行中。